Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Clinical Oncology

• Publication date

  2011-10-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2010.33.7006PMID 21911723
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo

  2011cited by this paper
• Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents

  2011cited by this paper
• Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells

  2010cited by this paper
• Metformin and Other Biguanides in Oncology: Advancing the Research Agenda

  2010cited by this paper
• Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial.

  2009influential reference
• Gastrosplenic fistula from Hodgkin's lymphoma.

  2009cited by this paper
• Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer.

  2009cited by this paper
• Insulin and insulin-like growth factor signalling in neoplasia

  2008cited by this paper
• Calcium plus vitamin D supplementation and the risk of breast cancer.

  2008cited by this paper
• Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

  2007cited by this paper
• Centralized medical monitoring in phase III clinical trials: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience

  2006cited by this paper
• Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study.

  2002cited by this paper
• The NCIC CTG MA.14 experience with the gallbladder toxicity of octreotide pamoate (oncolar) in a postmenopausal patient population undergoing adjuvant treatment for stage 1-3 breast cancer

  2002cited by this paper
• Coronary heart disease mortality and adjuvant tamoxifen therapy.

  1997cited by this paper
• Octreotide.

  1996cited by this paper
• Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(alpha)anthracene-induced rat mammary carcinomas.

  1994cited by this paper
• Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2.

  1994cited by this paper
• Somatostatin-receptor scintigraphy in primary breast cancer.

  1994cited by this paper
• Somatostatin analogs for diagnosis and treatment of cancer.

  1993cited by this paper
• Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors.

  1991cited by this paper
• Advanced breast cancer: response to somatostatin.

  1990cited by this paper
• Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients.

  1990cited by this paper
• Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer.

  1989cited by this paper
• Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I.

  1989cited by this paper
• Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells.

  1987cited by this paper
• Testing for qualitative interactions between treatment effects and patient subsets.

  1985cited by this paper
• Discrete sequential boundaries for clinical trials

  1983cited by this paper

• Detection of Somatostatin Receptors by Ligand Derivative Staining in Breast Tumors

  2025cites this paper
• The State-of-the-Art Mechanisms and Antitumor Effects of Somatostatin in Colorectal Cancer: A Review

  2024cites this paper
• Comparison of the effects of high-intensity interval and moderate-intensity continuous training on inflammatory markers, cardiorespiratory fitness, and quality of life in breast cancer patients

  2023cites this paper
• The Mechanism of Action of Biguanides: New Answers to a Complex Question

  2022cites this paper
• Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta‐analysis

  2022cites this paper
• Postdiagnosis dietary factors, supplement use and breast cancer prognosis: Global Cancer Update Programme (CUP Global) systematic literature review and meta‐analysis

  2022cites this paper
• New perspectives in macromolecular powder diffraction using single-photon-counting strip detectors: high-resolution structure of the pharmaceutical peptide octreotide.

  2021cites this paper
• Vitamin D Status and Cancer Incidence, Survival, and Mortality.

  2020cites this paper
• Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations

  2019cites this paper
• Octreotide

  2019cites this paper
• Revisiting the structure of a synthetic somatostatin analogue for peptide drug design.

  2019cites this paper
• YEARS OF IGF 1 Anti-insulin-like growth factor therapy in breast cancer

  2018cites this paper
• Anti-insulin-like growth factor therapy in breast cancer.

  2018cites this paper
• Aiming for the Insulin-like Growth Factor-1 system in breast cancer therapeutics.

  2018cites this paper
• A reappraisal on metformin

  2018cites this paper
• Obesity and breast cancer – what’s new?

  2017cites this paper
• Clinical studies in humans targeting the various components of the IGF system show lack of efficacy in the treatment of cancer.

  2017cites this paper
• Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials

  2017cites this paper
• Novel contribution of chromatography in the development and analyses of metformin hydrochloride in biological and environmental samples

  2017cites this paper
• Lack of cortistatin or somatostatin differentially influences DMBA-induced mammary gland tumorigenesis in mice in an obesity-dependent mode

  2016cites this paper
• Overcoming Endocrine Resistance

  2016cites this paper
• Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14

  2016cites this paper
• Reducing the Risk of Breast Cancer Recurrence: an Evaluation of the Effects and Mechanisms of Diet and Exercise

  2016cites this paper
• Impact of the obesity epidemic on cancer.

  2015cites this paper
• Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer

  2015cites this paper
• Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29

  2015cites this paper
• A male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression

  2015cites this paper
• Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.

  2015cites this paper
• Host Factors and Risk of Breast Cancer Recurrence: Genetic, Epigenetic and Biologic Factors and Breast Cancer Outcomes.

  2015cites this paper
• Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32.

  2015cites this paper
• Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

  2015cites this paper
• The Globalization of Cooperative Groups.

  2015cites this paper
• Somatostatin Analogues Use in Other than Endocrine Tumor Indications

  2015cites this paper
• Analyses of Biguanides and Related Compounds in Biological and Environmental Samples by HPLC

  2015cites this paper
• Effect of Metformin vs Placebo on Weight and Metabolic Factors in NCIC CTG MA.32

  2015cites this paper
• The insulin-like growth factor 1 axis in prognosis and treatment of breast cancer

  2014cites this paper
• Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial

  2014cites this paper
• Inconsistent selection and definition of local and regional endpoints in breast cancer research

  2014cites this paper
• Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial

  2014cites this paper
• The Anticancer Effect of Metformin, the Most Commonly Used Anti-Diabetes Drug

  2014cites this paper
• Competing risks of death in younger and older postmenopausal breast cancer patients.

  2014cites this paper
• Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial.

  2014cites this paper
• Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence

  2014cites this paper
• Expression of somatostatin type-2 and -4 receptor and correlation with histological type in breast cancer.

  2014cites this paper
• Circulating 25‐hydroxyvitamin D and postmenopausal breast cancer survival: Influence of tumor characteristics and lifestyle factors?

  2014cites this paper
• Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer.

  2013cites this paper
• Insulin and IGFs in Obesity-Related Breast Cancer

  2013cites this paper
• Potential applications for biguanides in oncology.

  2013cites this paper
• Correlation of immunohistopathological expression of somatostatin receptor-2 in breast cancer and tumor detection with 68Ga-DOTATOC and 18F-FDG PET imaging in an animal model.

  2013cites this paper
• Insulin-like growth factor - oestradiol crosstalk and mammary gland tumourigenesis.

  2013cites this paper
• Epidemiology and Molecular Mechanisms Tying Obesity, Diabetes, and the Metabolic Syndrome With Cancer

  2013cites this paper
• Somatostatin receptors: from signaling to clinical practice.

  2013cites this paper
• The epidemiology and molecular mechanisms linking obesity, diabetes, and cancer.

  2013cites this paper
• Efficacy of combined therapy of goserelin and letrozole on very young women with advanced breast cancer as first-line endocrine therapy.

  2013cites this paper
• Hormone Receptors and Endocrine Therapy in Breast Cancer

  2013cites this paper
• Review of the Impact of Antineoplastic Therapies on the Risk for Cholelithiasis and Acute Cholecystitis

  2013cites this paper
• Evolving Treatment Strategies for Management of Carcinoid Tumors

  2013cites this paper
• Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review

  2013cites this paper
• Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review.

  2013cites this paper
• Nutrition and physical activity influence on breast cancer incidence and outcome.

  2013cites this paper
• Two birds with one stone: octreotide treatment for acromegaly and breast cancer.

  2013cites this paper
• Peptide Receptor Targeting in Cancer: The Somatostatin Paradigm

  2013cites this paper
• Post-surgical highly sensitive C-reactive protein and prognosis in early-stage breast cancer

  2013cites this paper
• The Role of Obesity in Cancer Survival and Recurrence

  2012cites this paper
• Alternative Approach to Insulin-Like Growth Factor-1 Inhibition for Treatment of Breast Cancer

  2012cites this paper
• Vitamin D and breast cancer incidence and outcome.

  2012cites this paper
• Effect of Exercise on Markers of Inflammation in Breast Cancer Survivors: The Yale Exercise and Survivorship Study

  2012cites this paper
• The insulin and insulin-like growth factor receptor family in neoplasia: an update

  2012cites this paper
• Reply to P. Ameri et al

  2012cites this paper
• Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations.

  2012cites this paper
• Targeting insulin-like growth factor in breast cancer therapeutics.

  2012cites this paper
• TITLE : Effect of Exercise on Markers of Inflammation in Breast Cancer Survivors : The Yale Exercise and Survivorship Study Running Title : Exercise and Inflammatory Markers in Breast Cancer Survivors

  2012cites this paper
• Pre-Eclampsia and Breast Cancer Risk: “Fertile” Ground for Elucidating New Mechanisms of Prevention?

  2012cites this paper
• Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.

  2012cites this paper
• Diabetes, metformin, and breast cancer: lilac time?

  2012cites this paper
• Aromatase inhibition in obese women: how much is enough?

  2012cites this paper
• Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors.

  2012cites this paper
• Alternative approach to insulin-like growth factor-1 inhibition for treatment of breast cancer.

  2012cites this paper
• Metformin in cancer: translational challenges.

  2012cites this paper
• Decision-making tools to assist prognosis and treatment choices in early breast cancer: a review

  2012cites this paper
• Investigating metformin for cancer prevention and treatment: the end of the beginning.

  2012cites this paper
• Insulinemia and the risk of breast cancer and its relapse

  2012cites this paper
• The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology

  2012cites this paper
• tor family targeting agents in breast cancer may be justified.

  2012cites this paper
• Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study

  2012influential citation
• Hormonal Resistance in Breast Cancer: Evolving Treatment Strategies

  2012cites this paper
• Obesity and Insulin Resistance in Breast Cancer: Are Clinical Trials Needed?

  2012cites this paper
• IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer.

  2011cites this paper
• Targeting the insulin-like growth factor pathway in estrogen receptor-positive breast cancer: a bumpy start with an uncertain future.

  2011cites this paper